TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37419638

Group type: EXPERIMENTAL
Intervention: Ivermectin mass drug administration (MDA) combined with artemisinin-based combination therapy (ACT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 37419646

Group type: EXPERIMENTAL
Intervention: Conditioned open-label placebo (COLP) group receiving conditioning with clove oil scent paired with active and placebo opioids for 5 days, in addition to standard multimodal analgesia including opioids.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard multimodal analgesia including opioids (control group).
Number of subjects: 0
Study: 37419693

Group type: EXPERIMENTAL
Intervention: Neqstent coil-assisted flow diverter (NQS) with platinum coils
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: NQS
Number of subjects: 38
Study: 37419867

Group type: EXPERIMENTAL
Intervention: Platinum doublet therapy
Number of subjects: 697

Group type: COMPARATOR
Intervention: Carboplatin
Number of subjects: 697

Group type: COMPARATOR
Intervention: Single-agent immunotherapy
Number of subjects: 697
Study: 37419969

Group type: EXPERIMENTAL
Intervention: Nutritional support
Number of subjects: 763

Group type: COMPARATOR
Intervention: Usual hospital food (control)
Number of subjects: 763
Study: 37419971

Group type: EXPERIMENTAL
Intervention: NWT-03 supplementation
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: NWT-03 supplementation (acute intake after intervention)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control
Number of subjects: 76
Study: 37420006

Group type: EXPERIMENTAL
Intervention: IL-1β-neutralizing antibody canakinumab
Number of subjects: 25
Study: 37420013

Group type: EXPERIMENTAL
Intervention: Dizziness
Number of subjects: 10092

Group type: EXPERIMENTAL
Intervention: Falls
Number of subjects: 10092

Group type: EXPERIMENTAL
Intervention: Treatment for dizziness
Number of subjects: 10092

Group type: EXPERIMENTAL
Intervention: Self-perceived health
Number of subjects: 10092

Group type: EXPERIMENTAL
Intervention: Falls and treatment for dizziness
Number of subjects: 10092

Group type: EXPERIMENTAL
Intervention: Hearing loss
Number of subjects: 10092

Group type: EXPERIMENTAL
Intervention: Dizziness and self-perception of health
Number of subjects: 10092

Group type: EXPERIMENTAL
Intervention: Dizziness treatment
Number of subjects: 10092
Study: 37420180

Group type: EXPERIMENTAL
Intervention: Family centered care (FCC) intervention with additional elements rolled out in a stepwise 6-month approach including NICU environment changes, staff training, parental education, and psychosocial support for parents.
Number of subjects: 0
Study: 37420227

Group type: EXPERIMENTAL
Intervention: 3D-CBCT sialography
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: MR sialography
Number of subjects: 46
Study: 37420268

Group type: EXPERIMENTAL
Intervention: Digital therapy (Playball)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Non-digital therapy
Number of subjects: 22
Study: 37420274

Group type: EXPERIMENTAL
Intervention: PF-06804103 3.0 mg/kg Q3W
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: PF-06804103 4.0 mg/kg Q3W
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: PF-06804103 (all doses)
Number of subjects: 93
Study: 37420284

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention including A&F report, educational meetings, and facilitation visits
Number of subjects: 30

Group type: COMPARATOR
Intervention: Simple Audit & Feedback (A&F)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention
Number of subjects: 30
Study: 37421271

Group type: EXPERIMENTAL
Intervention: Kansas City Cardiomyopathy Questionnaire-12 at admission and 1, 6, and 12 months after discharge
Number of subjects: 2328

Group type: EXPERIMENTAL
Intervention: Advanced age, decompensated chronic HF, HF with mildly reduced ejection fraction, HF with preserved ejection fraction, depression symptoms, cognitive impairment, and each additional HF rehospitalization within 1 year of discharge
Number of subjects: 2328
Study: 37421269

Group type: EXPERIMENTAL
Intervention: Postcardiotomy ECMO
Number of subjects: 2058
Study: 37421276

Group type: EXPERIMENTAL
Intervention: One-third anterior-posterior diameter (APD) measurement in infants
Number of subjects: 182

Group type: EXPERIMENTAL
Intervention: One-third anterior-posterior diameter (APD) measurement in children
Number of subjects: 182
Study: 37421278

Group type: EXPERIMENTAL
Intervention: Tmax mismatch ratio >10 s/>6 s
Number of subjects: 213
Study: 37421291

Group type: EXPERIMENTAL
Intervention: TEER with MitraClip plus guideline-directed medical therapy (GDMT)
Number of subjects: 614

Group type: COMPARATOR
Intervention: GDMT alone
Number of subjects: 614
Study: 37421320

Group type: EXPERIMENTAL
Intervention: In-laboratory titration polysomnography (tPSG)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Efficacy home sleep study (eHST)
Number of subjects: 60
Study: 37421604

Group type: EXPERIMENTAL
Intervention: Crovalimab (C5 inhibitor), loading doses (one intravenous, four subcutaneous) and subsequent every-4-weeks subcutaneous maintenance doses per weight-based tiered-dosing schedule.
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Crovalimab (C5 inhibitor)
Number of subjects: 51
Study: 37421844

Group type: EXPERIMENTAL
Intervention: Resistance training (3 days/week for 15 weeks)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control (unchanged physical activity)
Number of subjects: 65
Study: 37421995

Group type: EXPERIMENTAL
Intervention: Plain Language Recommendation (PLR)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Standard Language Version (SLV)
Number of subjects: 295
Study: 37422010

Group type: EXPERIMENTAL
Intervention: Enhanced, prolonged and intensified ECG-monitoring with continuous rhythm monitoring using an implantable cardiac monitor (ICM) for high-risk patients and repeated 7-day Holter ECGs for others.
Number of subjects: 5200

Group type: COMPARATOR
Intervention: Standard of care monitoring (control arm) with rhythm monitoring at the discretion of participating centers, allowed for up to 7 days.
Number of subjects: 5200
Study: 37422079

Group type: EXPERIMENTAL
Intervention: Rilematovir 500 mg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Rilematovir 80 mg
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 37422192

Group type: EXPERIMENTAL
Intervention: Complete HRM-BR
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Partial/absent HRM-BR
Number of subjects: 207
Study: 37422199

Group type: EXPERIMENTAL
Intervention: Total aPS/PT
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: LAC potency
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: aPC-R
Number of subjects: 83
Study: 37422241

Group type: EXPERIMENTAL
Intervention: Oral sulfate solution (OSS)
Number of subjects: 348

Group type: COMPARATOR
Intervention: 3-L polyethylene glycol (PEG)
Number of subjects: 348
Study: 37422250

Group type: EXPERIMENTAL
Intervention: Separated instrument removal (RSI) using a modified spinal needle technique
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: RSI technique
Number of subjects: 158
Study: 37422518

Group type: EXPERIMENTAL
Intervention: SCTV01E (30 µg)
Number of subjects: 450

Group type: COMPARATOR
Intervention: SCTV01C (20 µg)
Number of subjects: 450

Group type: COMPARATOR
Intervention: BNT162b2 (20 µg)
Number of subjects: 450
Study: 37422659

Group type: EXPERIMENTAL
Intervention: Psychological intervention targeting the mechanism (6 sessions over 8 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Assessment of the causes of incapacity (control condition, 6 sessions over 8 weeks)
Number of subjects: 60
Study: 37422666

Group type: EXPERIMENTAL
Intervention: Continuous intravenous unfractionated heparin (UFH) therapy
Number of subjects: 456

Group type: COMPARATOR
Intervention: Subcutaneous low-molecular-weight heparin (LMWH) injection
Number of subjects: 456
Study: 37422688

Group type: EXPERIMENTAL
Intervention: Azacitidine 75 mg/m², venetoclax, and pevonedistat
Number of subjects: 40
Study: 37422751

Group type: EXPERIMENTAL
Intervention: Cervical spine manipulation (EG, n=25)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham-control (CG, n=25, 23 completed)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 37422752

Group type: EXPERIMENTAL
Intervention: Mulligan's mobilization with movement (MWM)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sham application (control)
Number of subjects: 56
Study: 37422772

Group type: EXPERIMENTAL
Intervention: BAY1128688 3 mg once daily
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: BAY1128688 10 mg once daily
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: BAY1128688 30 mg once daily
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: BAY1128688 30 mg twice daily
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: BAY1128688 60 mg twice daily
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 37422841

Group type: EXPERIMENTAL
Intervention: Heart rate variability (HRV) markers
Number of subjects: 3289

Group type: EXPERIMENTAL
Intervention: Non-linear HRV measures
Number of subjects: 3289

Group type: EXPERIMENTAL
Intervention: Multivariable linear regression analyses
Number of subjects: 3289

Group type: EXPERIMENTAL
Intervention: Cox regression analyses
Number of subjects: 3289
Study: 37423228

Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg IV every 3 weeks)
Number of subjects: 453

Group type: COMPARATOR
Intervention: Single-agent chemotherapy (vinorelbine or gemcitabine, dosing per local label)
Number of subjects: 453
Study: 37423231

Group type: EXPERIMENTAL
Intervention: Baricitinib (4 mg once daily)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Baricitinib
Number of subjects: 220
Study: 37423623

Group type: EXPERIMENTAL
Intervention: CAB+RPV long-acting (LA) administration
Number of subjects: 0
Study: 37423647

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Certolizumab
Number of subjects: 812

Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 812

Group type: COMPARATOR
Intervention: Active conventional therapy
Number of subjects: 812
Study: 37423676

Group type: EXPERIMENTAL
Intervention: Self-affirmation audio recording for three days after surgery
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 61
Study: 37423717

Group type: EXPERIMENTAL
Intervention: Mepolizumab 300 mg monthly for 3 months
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Mepolizumab 300 mg monthly for 6 months (mepo/mepo)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo followed by Mepolizumab 100 mg monthly for 3 months (pbo/mepo)
Number of subjects: 66
Study: 37423801

Group type: EXPERIMENTAL
Intervention: H-SC (600 mg fixed-dose)
Number of subjects: 113

Group type: COMPARATOR
Intervention: H-SC
Number of subjects: 113
Study: 37423834

Group type: EXPERIMENTAL
Intervention: Fosaprepitant 150 mg i.v. dissolved in 0.9% saline 150 ml
Number of subjects: 1154

Group type: COMPARATOR
Intervention: Placebo (0.9% saline 150 ml)
Number of subjects: 1154
Study: 37423882

Group type: EXPERIMENTAL
Intervention: Interleukin (IL)-1β
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interleukin (IL)-6
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor (TNF)
Number of subjects: 0
Study: 37423902

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy for insomnia (CBT-I)
Number of subjects: 22
Study: 37423933

Group type: EXPERIMENTAL
Intervention: NephroCheck bedside system
Number of subjects: 45
Study: 37424023

Group type: EXPERIMENTAL
Intervention: Duhuo Jisheng Decoction (DHJSD) plus Tui-na manipulation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Tui-na manipulation alone
Number of subjects: 70
Study: 37424311

Group type: EXPERIMENTAL
Intervention: Legume group (20% TPI, 200 g RPM per week)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Meat group (25% TPI, 760 g RPM per week)
Number of subjects: 102
Study: 37424386

Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Ribociclib
Number of subjects: 139
Study: 37424700

Group type: EXPERIMENTAL
Intervention: DLBS3233 (100 mg once per day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Metformin XR (750 mg twice per day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: DLBS3233 (100 mg once per day) + Metformin XR (750 mg twice per day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 37424866

Group type: EXPERIMENTAL
Intervention: Increased myocardial triglyceride content (MTGC)
Number of subjects: 338
Study: 37425161

Group type: EXPERIMENTAL
Intervention: Supportive care mobile application combined with usual oncology care
Number of subjects: 120

Group type: COMPARATOR
Intervention: Usual oncology care alone
Number of subjects: 120
Study: 37425294

Group type: EXPERIMENTAL
Intervention: Behavior Rating Inventory of Executive Function (BRIEF) self-rating
Number of subjects: 144

Group type: COMPARATOR
Intervention: Behavior Rating Inventory of Executive Function (BRIEF) parent-rating
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Impulsivity and Emotion Dysregulation Scale (IED-27)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Overall assessment of executive functioning
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Training of executive functioning
Number of subjects: 144
Study: 37425298

Group type: EXPERIMENTAL
Intervention: TTV load and QF-Ag
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: TTV load and QF-Mg
Number of subjects: 64
Study: 37425372

Group type: EXPERIMENTAL
Intervention: Hybrid epicardial-endocardial ablation (HA)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Endocardial ablation (CA)
Number of subjects: 154
Study: 37425493

Group type: EXPERIMENTAL
Intervention: Diagnostic arrays
Number of subjects: 755
Study: 37425721

Group type: EXPERIMENTAL
Intervention: Chronically implanted brain-computer interface (BCI)
Number of subjects: 1
Study: 37425726

Group type: EXPERIMENTAL
Intervention: MtrCDE efflux pump
Number of subjects: 0
Study: 37426086

Group type: EXPERIMENTAL
Intervention: Serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) treatment
Number of subjects: 238
Study: 37426102

Group type: EXPERIMENTAL
Intervention: Family psychoeducation intervention (six sessions over 1.5 months)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 25
Study: 37426178

Group type: EXPERIMENTAL
Intervention: Nasafytol
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 25
Study: 37426179

Group type: EXPERIMENTAL
Intervention: Intervention diet (rich in whole grain, fruit and vegetables, margarine/oil and seafood)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control diet (rich in meat and high-fat dairy)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intervention diet
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 50
Study: 37426430

Group type: EXPERIMENTAL
Intervention: Mesenchymal stromal cells (MSC) infusion at 6 and 7 weeks post-transplantation
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no MSC infusion)
Number of subjects: 34
Study: 37426947

Group type: EXPERIMENTAL
Intervention: Pre-Delta
Number of subjects: 4113

Group type: EXPERIMENTAL
Intervention: Delta
Number of subjects: 4113

Group type: EXPERIMENTAL
Intervention: Omicron
Number of subjects: 4113
Study: 37426952

Group type: EXPERIMENTAL
Intervention: COVID-positive participants
Number of subjects: 5963

Group type: COMPARATOR
Intervention: COVID-negative participants
Number of subjects: 5963

Group type: EXPERIMENTAL
Intervention: General and fatigue-related symptoms
Number of subjects: 5963

Group type: EXPERIMENTAL
Intervention: Symptom classes at 3 months
Number of subjects: 5963
Study: 37427145

Group type: EXPERIMENTAL
Intervention: R-CHOP-21 with radiotherapy
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: R-CHOP-14 with radiotherapy
Number of subjects: 131

Group type: COMPARATOR
Intervention: R-CHOP-21 without radiotherapy (observation)
Number of subjects: 131

Group type: COMPARATOR
Intervention: R-CHOP-14 without radiotherapy (observation)
Number of subjects: 131
Study: 37427146

Group type: EXPERIMENTAL
Intervention: R-CHOP-21 with radiotherapy
Number of subjects: 695

Group type: EXPERIMENTAL
Intervention: R-CHOP-14 with radiotherapy
Number of subjects: 695

Group type: COMPARATOR
Intervention: Observation after R-CHOP-21
Number of subjects: 695

Group type: COMPARATOR
Intervention: Observation after R-CHOP-14
Number of subjects: 695
Study: 37427254

Group type: EXPERIMENTAL
Intervention: Personal aptitudes related to behaviors (self-efficacy, activation, health literacy, resilience, locus of control, personality traits)
Number of subjects: 3083
Study: 37427292

Group type: EXPERIMENTAL
Intervention: Vadadustat
Number of subjects: 1725

Group type: COMPARATOR
Intervention: Darbepoetin alfa
Number of subjects: 1725

Group type: COMPARATOR
Intervention: Vadadustat vs Darbepoetin alfa
Number of subjects: 1725
Study: 37427566

Group type: EXPERIMENTAL
Intervention: Single SI (transplant to the duodenum)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Repeated SI (transplant to the duodenum twice)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: All treated groups (single LI, single SI, repeated SI)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 186
Study: 37427705

Group type: EXPERIMENTAL
Intervention: FX concentrate (Coagadex)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Monitoring FX activity post-surgery
Number of subjects: 2
Study: 37428030

Group type: EXPERIMENTAL
Intervention: Intervention to reduce cardiovascular risk; details on dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group; details not available.
Number of subjects: 0
Study: 37428131

Group type: EXPERIMENTAL
Intervention: Deep learning network (UNet)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Deep learning network (YNet)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Grader comparison
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Longitudinal GA lesion area enlargement correlations from screening to 12 months (n = 53)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Longitudinal GA lesion area enlargement correlations from screening to 6 months (n = 77)
Number of subjects: 337
Study: 37428139

Group type: EXPERIMENTAL
Intervention: Lactated Ringers (LR)
Number of subjects: 999

Group type: COMPARATOR
Intervention: Normal Saline (C)
Number of subjects: 999
Study: 37428195

Group type: EXPERIMENTAL
Intervention: Examined lymph node (ELN) count
Number of subjects: 7694

Group type: EXPERIMENTAL
Intervention: Optimal ELN count of 15
Number of subjects: 7694
Study: 37428273

Group type: EXPERIMENTAL
Intervention: SMAD4 methylation in BCC patients
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SMAD4 methylation in cSCC patients
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SMAD4 methylation in BSC patients
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SMAD4 mRNA expression in BCC patients
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SMAD4 mRNA expression in cSCC patients
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SMAD4 mRNA expression in BSC patients
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SMAD4 protein expression in cSCC patients
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SMAD4 mRNA levels in poorly differentiated cSCC patients
Number of subjects: 50
Study: 37428347

Group type: EXPERIMENTAL
Intervention: Palbociclib plus Aromatase Inhibitor (AI)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Aromatase Inhibitor (AI) monotherapy
Number of subjects: 196
Study: 37428348

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 110

Group type: COMPARATOR
Intervention: Iodopovidone
Number of subjects: 110
Study: 37428355

Group type: EXPERIMENTAL
Intervention: Telephone Health Coaching and Remote Exercise Monitoring for Peripheral Artery Disease (TeGeCoach) program
Number of subjects: 1685

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 1685
Study: 37428480

Group type: EXPERIMENTAL
Intervention: Abatacept (10 mg/kg; maximum dose, 1000 mg)
Number of subjects: 1971

Group type: EXPERIMENTAL
Intervention: Cenicriviroc (300-mg loading dose followed by 150 mg twice per day)
Number of subjects: 1971

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg)
Number of subjects: 1971

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1971
Study: 37428504

Group type: EXPERIMENTAL
Intervention: Deprescribing intervention (physician-pharmacist collaborative drug therapy management, standard-of-care practice recommendations, shared decision-making, and deprescribing protocols administered by telephone for a maximum of 180 days)
Number of subjects: 2470

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2470
Study: 37428533

Group type: EXPERIMENTAL
Intervention: Digital outpatient service intervention (6-month duration)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 165
Study: 37428547

Group type: EXPERIMENTAL
Intervention: AI platform (Eleos Health)
Number of subjects: 47

Group type: COMPARATOR
Intervention: TAU (treatment-as-usual)
Number of subjects: 47
Study: 37428653

Group type: EXPERIMENTAL
Intervention: Two-dose regimen of Ad5-nCoV vaccine
Number of subjects: 63

Group type: COMPARATOR
Intervention: One-dose regimen of Ad5-nCoV vaccine
Number of subjects: 63
Study: 37428681

Group type: EXPERIMENTAL
Intervention: Noxious stimulation during incision stage
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Noxious stimulation during insufflation stage
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Post-opioid administration
Number of subjects: 34
Study: 37428866

Group type: EXPERIMENTAL
Intervention: Supplemental ready-to-use therapeutic food (RUTF) with moderate-dose hydroxyurea therapy (20 mg/kg per day)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Supplemental ready-to-use therapeutic food (RUTF) without moderate-dose hydroxyurea therapy
Number of subjects: 110
Study: 37428883

Group type: EXPERIMENTAL
Intervention: Patient-centered group (informed preoperative education, choice of narcotic quantities)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Standard group (standard preoperative education, standard narcotic quantities)
Number of subjects: 154